Participated · Seed · Jul 2026

Prosper Medical operates an AI-enabled concierge primary care platform that aggregates patient health data, maintains continuity across interactions, coordinates care, and augments physician workflows with an AI care layer. Founded by Ryan McQuaid and Dr. James Wantuck (the founders of PlushCare), the company aims to deliver a personalized physician relationship at scale. Prosper is available to patients in all 50 states and is in-network with many major insurance plans. In its first months of operation the company has grown to serve thousands of members. Leadership frames the product as augmenting, not replacing, clinicians—combining Prosper AI, a Care Concierge Team, and doctors who arrive with patient context. The company plans to use recent financing to expand its physician network, further develop its AI platform, and accelerate market expansion.

Participated · Seed · Jul 2026

Porelio is a Germany-based deeptech startup founded in 2025 that develops Functionalized Ordered Mesoporous Silicas (FOMS) for industrial separation and water treatment. Its patented continuous-flow manufacturing process enables industrial-scale production of FOMS and is reported to be roughly 30 times faster than conventional production methods while operating under more sustainable conditions. The materials are regenerable and have shown strong performance in proof-of-concept projects across Europe, capturing palladium around six times faster than conventional adsorption technologies and removing more trifluoroacetic acid (TFA) than commercial activated carbon under comparable conditions. Porelio is moving from pilot-scale manufacturing measured in kilograms per day toward industrial production measured in tonnes per year. The company intends to use recent funding to accelerate technology development, scale production, and convert industrial collaborations into commercial partnerships. The articles do not disclose revenue, user counts, or valuation.

Participated · Seed · Apr 2026

Primogene develops and operates an enzymatic biomanufacturing platform to produce structurally complex biomolecules identical to their natural counterparts, including HMOs like DSLNT and difucosyllacto‑N‑tetraose I. The company manages the full value chain—enzyme development and production, biotransformation, and downstream processing—at its facility in Leipzig. It emphasizes enzymatic processes to overcome limitations of fermentation approaches and to enable scalable, cost‑efficient production of complex ingredients. Primogene holds an IP portfolio across several product categories and has established commercial partnerships in the personal care sector while pharmaceutical raw materials are in advanced customer evaluation. Founded in 2023, the company is expanding production capacity, growing its team, and seeking joint development partners among infant formula and functional food manufacturers. It is also collaborating with Fraunhofer IZI on infection‑prevention research and working with neonatal intensive care units to monitor HMO concentrations in breast milk.

Participated · Seed · Apr 2026

dehaze builds a purpose-built foundational AI model that processes heterogeneous healthcare datasets at scale to provide causal insights for clinicians and insurers. Its platform is designed to help healthcare payers identify individuals at risk of chronic conditions earlier, with the aim of improving intervention outcomes and reducing medical loss ratios. The company emphasizes that it is built as a foundational model for chronic disease detection rather than a chatbot or dashboard solution. dehaze says its system improves traceability and will add next-best-action recommendations to support decision-making. The company reports global customer interest and payer signings as it scales internationally.

Participated · Seed · Apr 2026

brainjo builds immersive, evidence-based VR Digital Health Applications designed to be prescribed by therapists or physicians and reimbursed by health insurers. Its solutions are intended to complement traditional psychotherapy by improving patient adherence and enabling accessible, at-home therapy. The company is developing its first VR DiGA for children with ADHD in collaboration with MEDICE – The Health Family. brainjo has secured €2 million in seed funding to finance a clinical study and pursue regulatory approval for that initial application. Market approval for the first DiGA is planned for 2028. The startup is headquartered in Regensburg and is backed by strategic partners and business angels alongside lead investor High-Tech Gründerfonds.